

Express Mail Label No. EV621477168US Dated: December 16 2005

Docket No.: 36119.140US2/AM100528
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Carl H. JUNE et al.

Application No.: 10/658,787

Confirmation No.: 1823

Filed: September 9, 2003

Art Unit: 1633

For: METHODS FOR TRANSFECTING T CELLS

Examiner: M. Leavitt

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This Information Disclosure Statement is being filed after the mailing date of the first Office Action on the merits and before the mailing date of a final Office Action or a Notice of Allowance.

Please charge the \$180.00 fee to our Deposit Account No. 08-0219.

Applicants request that the Examiner initial and return a copy of the enclosed Form PTO SB-08 with the next communication.

Dated: December 15, 2005

Respectfully submitted,

By Colleen Superko
Colleen Superko

Registration No.: 39,850
WILMER CUTLER PICKERING HALE AND
DORR LLP
60 State Street
Boston, Massachusetts 02109
(617) 526-6000
Attorney for Applicants

12/19/2005 MBIZUNES 00000061 080219 10658787

01 FC:1806 180.00 DA



Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/658,787 – Conf. #1823	
			Filing Date	September 9, 2003	
			First Named Inventor	Carl H. JUNE et al.	
			Art Unit	1633	
			Examiner Name	M. Leavitt	
Sheet	1	of	2	Attorney Docket Number	36119.140US2/AM100528

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA*	US-5,272,082	12-21-1993	Santoli et al.	
	AB*	US-5,399,346	03-21-1995	Anderson et al.	
	AC*	US-5,443,983	08-22-1995	Ochoa et al.	
	AD*	US-5,733,543	03-31-1998	Nabel et al.	
	AE*	US-5,738,852	04-14-1998	Robinson et al.	
	AF*	US-5,827,642	10-27-1998	Riddell et al.	
	AG*	US-5,858,358	01-12-1999	June et al.	
	AH*	US-6,692,964	02-17-2004	June et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	BA	WO-90/05541	05-31-1990	THE REGENTS OF THE UNIVERSITY OF MICHIGAN		
	BB	WO-94/12196	06-09-1994	TANOX BIOSYSTEMS, INC.		
	BC	WO-94/29436	12-22-1994	THE UNITED STATES OF AMERICA represented by THE SECRETARY OF THE NAVY		
	BD	WO-95/03408	02-02-1995	DANA-FARBER CANCER INSTITUTE		
	BE	WO-95/33823	12-14-1995	THE UNITED STATES OF AMERICA, represented by THE SECRETARY OF THE NAVY		
	BF	WO-95/34320	12-21-1995	REGENTS OF THE UNIVERSITY OF MINNESOTA		
	BG	WO-96/01122	01-18-1996	DANA-FARBER CANCER INSTITUTE		
	BH	WO-96/02646	02-01-1996	CYTOTHERAPEUTICS, INC.		
	BI	WO-96/06942	03-07-1996	MAX-PLANCK- GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, ...)	
Examiner Signature		Date Considered	

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/658,787 – Conf. #1823
				Filing Date	September 9, 2003
				First Named Inventor	Carl H. JUNE et al.
				Art Unit	1633
				Examiner Name	M. Leavitt
Sheet	2	of	2	Attorney Docket Number	36119.140US2/AM100528

Initials	No. ¹	magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Cann et al., "High Efficiency Transfection of Primary Human Lymphocytes and Studies of Gene Expression," <i>Oncogene</i> , 3:122-128 (1988)	
	CB	Coghlan, "Gene Dream Fades Away" <i>New Scientist</i> , 148: 14-15 (1995)	
	CC	Crystal, "Transfer of Genes to Humans: Early Lessons and Obstacles to Success" <i>Science</i> , 270:404-410 (1995)	
	CD	Fausser, "Long-Term Expression of Gene Introduction into Normal Human T-Lymphocytes by Retroviral-Mediated Gene Transfer," <i>Journal of Cellular Biochemistry</i> , 45:353-358 (1991)	
	CE	Finer et al., "kat: A High-Efficiency Retroviral Transduction System for Primary Human T Lymphocytes," <i>Blood</i> , 83(1):43-50 (1994)	
	CF	Guba et al., "Interleukin-3 Gene Induction in Normal Human T Cells Via Stimulation of CD3 and CD28," <i>Clinical Research</i> , 37(4) (1989)	
	CG	Gunzburg et al., "Virus Vector Design in Gene Therapy" <i>Molecular Medicine Today</i> , 410-417 (1995)	
	CH	Lowenthal et al., "Tumor Necrosis Factor α Induces Proteins that Bind Specifically to kB-like Enhancer Elements and Regulate Interleukin 2 Receptor α -chain Gene Expression in Primary Human T Lymphocytes," <i>PNAS USA</i> , 86:2331-2335 (1989)	
	CI	Mastrangelo et al. "Gene Therapy for Human Cancer: An Essay for Clinicians" <i>Seminars In Oncology</i> , 23(1):4-21 (1996)	
	CJ	Novak et al., "In Vitro Transfection of Fresh Thymocytes and T Cells Shows SUBset-Specific Expression of Viral Promoters," <i>Molecular and Cellular Biology</i> , 12:1515-1527 (1992)	
	CK	Orkin et al. "Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy" pp. 21-22, December (1995)	
	CL	Park et al., "Transcriptional Regulation of Interleukin 3 (IL3) in Primary Human T Lymphocytes," <i>Journal of Biological Chemistry</i> , 268(9):6299-6308 (1993)	
	CM	Philip et al., "Efficient and Sustained Gene Expression in Primary T Lymphocytes and Primary and Cultured Tumor Cells Mediated by Adeno-Associated Virus Plasmid DNA Complexed to Cationic Liposomes," <i>Molecular and Cellular Biology</i> , 14:2411-2418 (1994)	
	CN	Tiberghien et al., "Ganciclovir Treatment of Herpes Simplex Thymidine Kinase-Transduced Primary T Lymphocytes: An Approach for Specific In Vivo Donor T-Cell Depletion After Bone Marrow Transplantation?" <i>Blood</i> , 84(4):1333-1341 (1994)	
	CO	Verma et al., "Gene therapy-promise, problems, and prospects" <i>Nature</i> , 389:239-242 (1997)	
	CP	Weiss, "T Lymphocyte Activation", ch. 13, <i>Fundamental Immunology</i> , Second Edition, ed. by WE Paul, Raven Press Ltd., New York, pp. 359-384 (1989)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

5412706

US1DOCS 5412706v1